(:NMTR)

May 30, 2023 09:25 am ET
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.
May 15, 2023 05:15 pm ET
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.
Apr 05, 2023 08:00 am ET
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the compl
Mar 28, 2023 08:00 am ET
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
RALEIGH, NC / ACCESSWIRE / March 28, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2022.
Mar 15, 2023 04:05 pm ET
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
RALEIGH, NC / ACCESSWIRE / March 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today the closing of its previously announced registered direct offering of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock equivalent) and accompanying warrant priced at-the-market under Nasdaq rules. The warra
Mar 14, 2023 08:00 am ET
9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
RALEIGH, NC / ACCESSWIRE / March 14, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock equivalent) and accompanying warrant in a registered direct
Mar 07, 2023 08:00 am ET
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present at the Oppenheimer 33rd Annual Healthcare Conference.
Jan 31, 2023 08:00 am ET
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
RALEIGH, NC / ACCESSWIRE / January 31, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters is scheduled to present on Monday, February 6, 2023, at 10:00 AM ET as part of the BIO CEO & Investor Conference being held in New York City.
Nov 29, 2022 08:00 am ET
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / November 29, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced the design of its Phase 3 clinical trial of vurolenatide for adults with short bowel syndrome (SBS). The study design follows the Company's successful End-of-Phase 2 meeting and incorporates input received from the U.S. Food and Drug Administration (FDA).
Nov 14, 2022 08:00 am ET
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy
RALEIGH, NC / ACCESSWIRE / November 14, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced a continuing collaboration agreement with Gustave Roussy, a world-renowned cancer center in France, using 9 Meters' small molecule tight junction microbiome modulator NM-102. NM-102 is presumed to prevent gut microbial metabolites and antigens from trafficking into the systemic circulation.
Nov 08, 2022 08:00 am ET
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
RALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended September 30, 2022.
Oct 24, 2022 08:00 am ET
9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific
RALEIGH, NC / ACCESSWIRE / October 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that M. Michael Wolfe, M.D., Professor of Physiology and Biophysics and former Chair of The Department of Medicine at Case Western Reserve University, MetroHealth Campus, delivered two poster presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, taking place in Charlotte, North Carolina, on October 21-26, 2022.
Oct 18, 2022 08:00 am ET
9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
RALEIGH, NC / ACCESSWIRE / October 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced two poster presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting taking place in Charlotte, North Carolina on October 21-26, 2022. The posters highlight preclinical data investigating the use of humanized monoclonal antibodies (hu-mAbs) to glucose-dependent insulinotropic polypeptide (GIP). All research presented at A
Oct 17, 2022 08:00 am ET
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split
RALEIGH, NC / ACCESSWIRE / October 17, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 5:00 p.m. Eastern Time on October 17, 2022. 9 Meters common stock will begin trading on a split-adjusted basis commencing upon market open on October 18, 2022, under the Company's existing trading symbol &quo
Sep 27, 2022 10:56 am ET
Thinking about buying stock in American Virtual Cloud Technologies, Bed Bath & Beyond, Lucid Group, Plug Power, or 9 Meters Biopharma?
NEW YORK, Sept. 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVCT, BBBY, LCID, PLUG, and NMTR.
Sep 26, 2022 04:05 pm ET
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / September 26, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today positive final results from the Phase 2 study of vurolenatide and the outcome from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Vurolenatide is a proprietary long-acting GLP-1 receptor agonist in development for adults with short bowel syndrome (SBS). Based on the outcome from the meeting and the Phase 2 data, 9 Meters intends to final
Sep 06, 2022 08:30 am ET
9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
RALEIGH, NC / ACCESSWIRE / September 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022, in New York City. Management will also be hosting one-on-one meetings with investors.
Sep 01, 2022 08:00 am ET
9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress
RALEIGH, NC / ACCESSWIRE / September 1, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the company will participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress taking place September 3-6, 2022, in Vienna.
Aug 31, 2022 08:00 am ET
9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference
RALEIGH, NC / ACCESSWIRE / August 31, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company will participate in Citi's 17th Annual BioPharma Conference on September 8, 2022, in Boston.
Aug 15, 2022 07:00 am ET
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
RALEIGH, NC / ACCESSWIRE / August 15, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the second quarter ended June 30, 2022.
Jul 06, 2022 09:00 am ET
9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will participate in a fireside chat at the William Blair Biotech Focus Conference taking place on July 12 - 13, 2022, in New York City. Management will also be hosting one-on-one meetings with investors.
Jun 30, 2022 08:00 am ET
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome
Jun 30, 2022 07:00 am ET
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced positive preliminary topline results from the VIBRANT study (VurolenatIde for short Bowel syndrome Regardless of pArenteral support requiremeNT), its Phase 2 trial of vurolenatide, a proprietary, long-acting GLP-1 receptor agonist in development for the treatment of adult
Jun 21, 2022 08:00 am ET
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
RALEIGH, NC / ACCESSWIRE / June 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced completion of a pre-specified interim analysis for the Phase 3 study of larazotide, referred to as CedLara® (Celiac disease Larazotide), for patients with celiac disease who continue to experience gastrointestinal symptoms while adhering to a gluten-free diet. The interim analysis was conducted by an independent stat
Jun 13, 2022 04:35 pm ET
9 Meters Biopharma to Participate in the 2022 BIO International Convention
RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Company's participation in the 2022 BIO International Convention on June 13 - 16, 2022, in San Diego, California.
May 19, 2022 08:00 am ET
9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that the company will host an exhibit at Digestive Disease Week (DDW) which takes place May 21-24, 2022, in San Diego, CA.
May 18, 2022 08:00 am ET
9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis
RALEIGH, NC / ACCESSWIRE / May 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that Matthew Bryant, PharmD, Vice President of Medical Affairs at 9 Meters, delivered a poster presentation at the American Thoracic Society (ATS) International Conference, taking place in San Francisco May 13 - 18, 2022. The presentation highlighted preclinical data investigating the use of larazotide, a tight junction regulator, to redu
May 16, 2022 07:00 am ET
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022.
May 05, 2022 08:00 am ET
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
RALEIGH, NC / ACCESSWIRE / May 5, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the LifeSci Partners Immunology & Inflammation Symposium on May 10, 2022, and the H.C. Wainwright Global Investment Conference to be held on May 23-26, 2022.
Apr 20, 2022 09:00 am ET
9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease
RALEIGH, NC and SANTA ROSA, CA / ACCESSWIRE / April 20, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, and Celiac.com, a news, information, and support website for those on a gluten-free diet due to celiac disease or gluten sensitivity announced today a collaboration to further support clinical trial enrollment in 9 Meters' Phase 3 study known as CeDLara, for the drug candidate larazotide for celiac disease.
Apr 13, 2022 07:00 am ET
9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions
RALEIGH, NC / ACCESSWIRE / April 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.S. Patent Application No. 16/781,304 is allowed.
Mar 23, 2022 07:00 am ET
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021
RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2021.
Mar 21, 2022 08:00 am ET
9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
RALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the Maxim Group 2022 Virtual Growth Conference hosted by M-Vest on March 28 - 30, 2022.
Mar 09, 2022 08:00 am ET
9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / March 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022, at 10:00 a.m. (ET). The conference will take place on March 15-17, 2022, and is being held virtually.
Mar 02, 2022 08:00 am ET
9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder
RALEIGH, NC / ACCESSWIRE / March 2, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today a collaboration with NYU Langone Health investigating the pre-clinical use of 9 Meters' gut-restricted tight junction regulator, NM-102, for an undisclosed autoimmune condition with a large unmet need.
Feb 28, 2022 04:15 pm ET
9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease
RALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today an update on its late stage pipeline products vurolenatide, a proprietary long-acting glucagon-like peptide (GLP-1) agonist in a Phase 2 trial for adults with short bowel syndrome (SBS), and larazotide, a gut-selective tight junction modulator in a Phase 3 trial for celiac disease.
Feb 25, 2022 08:00 am ET
9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)
RALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the publication of encouraging data in the journal Critical Care Explorations, accessible online here, on the use of larazotide to treat pediatric patients with multisystem inflammatory syndrome in children (MIS-C) resulting from COVID-19. MIS-C is a rare but severe and potentially life-threatening condition that usually devel
Feb 09, 2022 08:00 am ET
9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference
RALEIGH, NC / ACCESSWIRE / February 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today that John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, Inc., will deliver a virtual presentation as part of the 2022 BIO CEO & Investor Conference taking place February 14-17, 2022.
Jan 24, 2022 08:00 am ET
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.S. Patent Application No. 17/239,056 is allowed.
Jan 18, 2022 08:00 am ET
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experience
Jan 05, 2022 08:31 am ET
Thinking about buying stock in 9 Meters Biopharma, TherapeuticsMD, Cameco Corp, Nikola Corp, or Comstock Mining?
NEW YORK, Jan. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NMTR, TXMD, CCJ, NKLA, and LODE.
Jan 04, 2022 07:30 am ET
9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
RALEIGH, NC / ACCESSWIRE / January 4, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced that the Company's CEO, John Temperato along with other management team members will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings. Please see additional details below:
Jan 03, 2022 07:30 am ET
9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications.
Dec 28, 2021 08:31 am ET
Thinking about buying stock in Energy Focus, 9 Meters Biopharma, Aditxt, ReTo Eco-Solutions, or Aeva Technologies?
NEW YORK, Dec. 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EFOI, NMTR, ADTX, RETO, and AEVA.
Dec 15, 2021 07:30 am ET
9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education
RALEIGH, NC / ACCESSWIRE / December 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced the company has awarded an unrestricted educational grant to Carol Rees Parrish, M.S., RDN, a GI Nutrition Support Specialist to support a new educational website: SBSCurbside. The educational service will allow Carol, who has longstanding expertise in caring for patients with short bowel syndrome (SBS), to provi
Nov 15, 2021 07:30 am ET
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
- Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 -- Larazotide Phase 3 for celiac disease interim analysis expected in Q2 2022 -- Appointed Samantha Ventimiglia of Vertex to the Board of Directors -- Quarter ending cash of $53.6 million is expected to fund operations into 2023 -
Nov 10, 2021 07:30 am ET
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
RALEIGH, NC / ACCESSWIRE / November 10, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced a collaboration agreement with Gustave Roussy, a leading cancer center in Villejuif, France, using 9 Meters' small molecule tight junction microbiome modulator NM-102. NM-102 is presumed to prevent gut microbial metabolites and antigens from trafficking into systemic circulation.
Nov 09, 2021 07:30 am ET
9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
RALEIGH, NC / ACCESSWIRE / November 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced that the Company's CEO, John Temperato is scheduled to present at the 12th Annual Jefferies London Healthcare Conference and invites investors to participate in one-on-one meetings both in person on Tuesday and Wednesday November 16th/17th or virtually on Thursday and Friday November 18th/19
Oct 26, 2021 07:30 am ET
9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021
- Vurolenatide's half-life is consistent with twice-monthly dosing -- Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year's end -
Oct 19, 2021 07:30 am ET
9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
RALEIGH, NC / ACCESSWIRE / October 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today that the company will deliver a poster presentation highlighting vurolenatide, 9 Meters' therapeutic candidate in short bowel syndrome, and will host a booth exhibit at the in-person component of the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting, held in a hybrid format both virtually and in Las Vegas, Nevada on
Oct 04, 2021 07:30 am ET
9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Samantha Ventimiglia to its Board of Directors.
Sep 27, 2021 07:30 am ET
9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
RALEIGH, NC / ACCESSWIRE / September 27, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced a partnership with Mend Hunger, a 501(c)(3) non-profit mobile food pantry organization that serves individuals and families in need of gluten-free food for medical and health reasons. The partnership will help Mend Hunger's Pantry Direct program to fulfill requests for gluten-free hunger relief boxes to families
Sep 22, 2021 08:15 am ET
Sep 08, 2021 08:15 am ET
Sep 01, 2021 08:15 am ET
Aug 12, 2021 08:30 am ET
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021
RALEIGH, NC / ACCESSWIRE / August 12, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR) (the "Company") is a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases or unique GI biology, today provided an overview of its recent achievements and reported financial results for the second quarter ended June 30, 2021.
Jul 19, 2021 08:30 am ET
9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity
- Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) -
Jul 12, 2021 11:30 am ET
Thinking about buying stock in Tencent Music Entertainment, Delta Air Lines, Iterum Therapeutics, HP, or 9 Meters Biopharma?
NEW YORK, July 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TME, DAL, ITRM, HPQ, and NMTR.
Jul 09, 2021 10:45 am ET
Thinking about buying stock in Dare Bioscience, Newegg, Zynga, 9 Meters Biopharma, or Kohl's?
NEW YORK, July 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, NEGG, ZNGA, NMTR, and KSS.
Jul 08, 2021 07:30 am ET
9 Meters Biopharma, Inc. To Present at the William Blair Biotech Focus Conference
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will participate in a virtual fireside chat at the William Blair Biotech Focus Conference being held July 14-15, 2021 and invites investors to join live via webcast.
Jun 28, 2021 07:30 am ET
9 Meters Added to Russell 2000(R) and 3000(R) Indexes
RALEIGH, NC / ACCESSWIRE / June 28, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell U.S. Indexes annual reconstitution. These updated Indexes will become effective after U.S. equity markets open today, Monday June 28, 2021.
Jun 14, 2021 07:30 am ET
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome
Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome
Jun 09, 2021 07:30 am ET
9 Meters Biopharma, Inc. to Present at 2021 BIO Digital
RALEIGH, NC / ACCESSWIRE / June 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will deliver a company presentation at 2021 BIO Digital being held June 10-11 & 14-18, 2021. 9 Meters invites investors to participate in live meetings on the BIO One-on-One Partnering™ system which will begin on June 14th.
Jun 01, 2021 07:30 am ET
9 Meters Biopharma, Inc. to Present at the Jefferies Virtual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will present at the Jefferies Virtual Healthcare Conference being held June 1- 4, 2021 and invites investors to participate via webcast and in one-on-one meetings. The presentation will be followed by a virtual Q&A session.
May 18, 2021 10:15 am ET
May 18, 2021 07:30 am ET
9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato will present a corporate update at Oppenheimer'sRare & Orphan Disease Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:
May 17, 2021 07:30 am ET
9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the United States Adopted Names (USAN) Council has officially designated the Company's long-acting injectable glucagon-like peptide-1 (GLP-1) receptor agonist drug candidate for short bowel syndrome, NM-002, as "vurolenatide."
May 13, 2021 07:30 am ET
9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021
- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023
Apr 21, 2021 07:30 am ET
9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit
RALEIGH, NC / ACCESSWIRE / April 21, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will participate in the 7th Annual Truist Securities Life Sciences Summit and invites investors to participate in one-on-one meetings. Please see additional details below:
Apr 19, 2021 07:30 am ET
9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will enter into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS).
Apr 12, 2021 07:30 am ET
9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study
RALEIGH, NC / ACCESSWIRE / April 12, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will collaborate with the Celiac Disease Foundation (CDF) to support clinical trial enrollment in 9 Meters' Phase 3 study, CeDLara, for their drug candidate larazotide in celiac disease.
Apr 05, 2021 04:15 pm ET
9 Meters Biopharma Announces Closing of Offering of Common Stock
RALEIGH, NC / ACCESSWIRE / April 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the closing of its previously announced underwritten public offering of 34,500,000 shares of its common stock, inclusive of the full overallotment option exercised by the underwriters, at a price to the public of $1.00 per share.
Mar 30, 2021 10:30 pm ET
9 Meters Biopharma Prices Public Offering of Common Stock
RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price to the public of $1.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 4,500,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on April 5, 2021, subject to customary cl
Mar 30, 2021 04:14 pm ET
9 Meters Biopharma Announces Proposed Public Offering of Common Stock
RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, 9 Meters Biopharma expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock to be sold in the offering. All of the shares in the proposed offering are to be sold by 9 Meters Biopharma. The offering is subject to market and other
Mar 22, 2021 04:00 pm ET
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020
Research & Development Day on Short Bowel Syndrome planned for tomorrow (March 23rd) at 11:00 AM ET - see https://media.rampard.com/20210323/reg.jsp for registration details
Mar 10, 2021 07:30 am ET
Mar 09, 2021 07:30 am ET
9 Meters Biopharma, Inc. Announces Chief Medical Officer's Presentation at NIH's Accelerating Progress in Celiac Disease Workshop
RALEIGH, NC / ACCESSWIRE / March 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that chief medical officer Patrick Griffin, M.D., FACP, will participate in an invited presentation at an upcoming virtual workshop entitled Accelerating Progress in Celiac Disease. The workshop is a National Institutes of Health workshop co-sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), to be held o
Mar 01, 2021 07:30 am ET
9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors
RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael Rice to its board of directors.
Feb 19, 2021 08:31 am ET
Thinking about buying stock in Gevo, Remark Holdings, 9 Meters Biopharma, Vertex Energy, or Grupo Supervielle?
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEVO, MARK, NMTR, VTNR, and SUPV.
Feb 10, 2021 07:30 am ET
9 Meters Biopharma, Inc. to Present at the 23rd Annual BIO CEO & Investor Conference
RALEIGH, NC / ACCESSWIRE / February 10, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that its Chief Executive Officer, John Temperato, will present a corporate overview and participate in one-on-one investor meetings at the BIO CEO & Investor Conference. The conference will be held virtually with all participants joining remotely February 16th - 18th.
Feb 03, 2021 07:30 am ET
9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities' CEO Strategic Vision Conference Call Series
RALEIGH, NC / ACCESSWIRE / February 3, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced its Executive Management team will participate in the "CEO Strategic Vision" Conference Call Series hosted by hosted by Srikripa Devarakonda, PhD and Robyn Karnauskas, PhD of Truist Securities on Wednesday, February 10, 2021. Please see additional details below:
Feb 01, 2021 07:30 am ET
9 Meters Biopharma, Inc. Announces Research & Development Day on Short Bowel Syndrome
SAVE THE DATE: Webinar Scheduled for March 23, 2021 @ 11 AM ET
Dec 21, 2020 07:30 am ET
9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications
RALEIGH, NC and SALERNO, ITALY / ACCESSWIRE / December 21, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced a collaboration with the European Biomedical Research Institute of Salerno (EBRIS), to advance to a study in order to evaluate the safety and tolerability of larazotide when delivered to lung tissue in healthy volunteers. Larazotide, a first-in-class tight junction modulator, is hypothesized to act on lung endothelial cells.
Dec 15, 2020 04:00 pm ET
9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock
RALEIGH, NC / ACCESSWIRE / December 15, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the closing of its previously announced underwritten public offering of 53,076,924 shares of its common stock, inclusive of the full overallotment option exercised by the underwriters, at a price to the public of $0.65 per share.
Dec 11, 2020 08:30 am ET
9 Meters Biopharma, Inc. Prices Public Offering of Common Stock
RALEIGH, NC / ACCESSWIRE / December 11, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the pricing of an underwritten public offering of 46,153,847 shares of its common stock at a price to the public of $0.65 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 6,923,077 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 15, 20
Dec 10, 2020 04:01 pm ET
9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock
RALEIGH, NC / ACCESSWIRE / December 10, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, 9 Meters Biopharma expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock to be sold in the offering. All of the shares in the proposed offering are to be sold by 9 Meters Biopharma. The offering is subject to market and other con
Dec 09, 2020 07:30 am ET
Dec 07, 2020 07:30 am ET
9 Meters Biopharma, Inc. Announces Positive Topline Data for NM-002, a Proprietary Long-Acting GLP-1, in Phase 1b/2a Trial for Short Bowel Syndrome
-Rapid onset and sustained clinical effect following first dose in all 9 patients in total stool output (TSO) volume-Clinically relevant improvements in TSO volume and bowel movement frequency-Twice-monthly fixed-dosing regimen exhibited an excellent safety and tolerability profile-Plan to meet with FDA as soon as possible in the first quarter of 2021 to discuss next steps for clinical development of NM-002
Nov 16, 2020 07:30 am ET
9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model
RALEIGH, NC / ACCESSWIRE / November 16, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced preliminary results from a collaboration with Gustave Roussy, Villejuif, France (a 14-months research project initiated in March 2019), using NM-102, a novel peptide that modulates intestinal permeability and the gut microbiome.
Nov 02, 2020 08:00 am ET
Sep 08, 2020 08:30 am ET
9 Meters Biopharma, Inc. to Participate in September Investor Conferences
H.C. Wainwright: 22nd Annual Global Investment ConferenceSeptember 14 - 16
Aug 31, 2020 08:30 am ET
9 Meters Biopharma, Inc. Announces Formation of Scientific Advisory Board
RALEIGH, NC / ACCESSWIRE / August 31, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the formation of its scientific advisory board (SAB). The SAB comprises an esteemed group of six experts in the gastroenterology field with sub-specialties in celiac disease, inflammatory bowel disease (IBD) and functional GI diseases. They will work closely with the 9 Meters leadership team in advancing the clinical development of the company's co-lead assets, NM-002 for the treatment of short bowel syndrome (SB
Aug 12, 2020 04:30 pm ET
9 Meters Biopharma, Inc. Provides Business Update and Announces Second Quarter 2020 Results
- Initiates Phase 1b/2a clinical trial with a proprietary long-acting GLP-1 agonist, in short bowel syndrome; first patients dosed in July and top-line data expected by Q1 2021 -
Aug 04, 2020 09:30 am ET
9 Meters Biopharma, Inc. to Participate in August Investor Conferences
-William Blair Biotech Focus Conference -August 4th- 6th
Jul 28, 2020 07:30 am ET
9 Meters Biopharma, Inc. Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS)
U.S. Pat. No. 10,723,763 issued on July 28, 2020, shows Larazotide reduces endothelial barrier permeability in a dose dependent fashion in both ALI and ARDS
Jul 21, 2020 07:45 am ET
9 Meters Biopharma, Inc. Doses the First Patients in Phase 1b/2a Clinical Trial in Short Bowel Syndrome
NM-002 is a long-acting GLP-1 agonist designed to address the gastric effects in SBS patients by slowing digestive transit time
Jul 13, 2020 10:26 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating 9 Meters Biopharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, July 13, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of 9 Meters Biopharma, Inc. (NASDAQ: NMTR).
Jul 06, 2020 04:15 pm ET
9 Meters Biopharma, Inc. Appoints Michael T. Constantino to Board of Directors
RALEIGH, NC / ACCESSWIRE / July 6, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael T. Constantino to its board of directors.
Jun 29, 2020 07:30 am ET
9 Meters Biopharma, Inc. Amends Definition of Primary Endpoint for Phase 3 Trial in Celiac Disease After Consultation with FDA
-New methodology enables a more capital-efficient study, with reduction in participants from 630 to 525 while maintaining statistical powering at 90%
Jun 24, 2020 04:05 pm ET
9 Meters Biopharma, Inc. Initiates Phase 1b/2a Clinical Trial in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / June 24, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced it has initiated its Phase 1b/2a clinical trial of NM-002 for the treatment of short bowel syndrome (SBS), a life-threatening orphan disease caused by a significant shortening of the gastrointestinal tract, leading to impaired nutrient absorption. NM-002 is a long-acting injectable glucagon-like peptide-1 (GLP-1) agonist designed specifically to exploit gut motility effects in SBS patients by slowing digestive transit
May 11, 2020 07:00 am ET
9 Meters Biopharma, Inc Receives Thorough QT Study Waiver by FDA for Larazotide Being Studied for Celiac Disease
US FDA grants request for a Thorough QT (TQT) waiver request based on larazotide's robust pre-clinical and clinical data
May 07, 2020 07:00 am ET
9 Meters Biopharma, Inc Announces the Closing of Naia Rare Diseases Acquisition
- Previously announced in late 2019 this transaction accelerates the development of novel long-acting GLP-1 receptor agonist as the Company's Co-Lead Program-
May 05, 2020 06:30 am ET
9 Meters Biopharma Hosting Research and Development Day
Will Provide Overview of Clinical Pipeline of Gastrointestinal Therapies in Short Bowel Syndrome and Celiac Disease
May 04, 2020 05:30 pm ET
9 Meters Biopharma, Inc Announces the Closing of $22.5 Million Private Placement Funding
RALEIGH, NC / ACCESSWIRE / May 4, 2020 / 9 Meters Biopharma, Inc (NASDAQ:NMTR), today announced that it has closed a private placement with existing and new investors to raise $22.5 million. The funding provides the capital for the soon to be launched Phase 1B/2A study for the first and only long-acting GLP-1 receptor agonist for the treatment of short bowel syndrome, and the top-line readout for the first-ever drug in a Phase 3 trial for celiac disease. The private placement was led Orbimed Advisors, LLC.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.